Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone866-788-9007
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees94
Next Earnings Date12/3/2019 (Estimated)
OptionableNot Optionable
Castle Biosciences (NASDAQ:CSTL) Frequently Asked Questions
What is Castle Biosciences' stock symbol?
Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL."
How were Castle Biosciences' earnings last quarter?
Castle Biosciences (NASDAQ:CSTL) released its quarterly earnings results on Tuesday, September, 3rd. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.54. The company had revenue of $10.74 million for the quarter, compared to analysts' expectations of $7.06 million. View Castle Biosciences' Earnings History.
When is Castle Biosciences' next earnings date?
What price target have analysts set for CSTL?
5 brokerages have issued 12-month target prices for Castle Biosciences' shares. Their predictions range from $28.00 to $34.00. On average, they expect Castle Biosciences' share price to reach $31.60 in the next year. This suggests a possible upside of 44.0% from the stock's current price. View Analyst Price Targets for Castle Biosciences.
What is the consensus analysts' recommendation for Castle Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Castle Biosciences.
Has Castle Biosciences been receiving favorable news coverage?
Media headlines about CSTL stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Castle Biosciences earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Castle Biosciences.
Who are some of Castle Biosciences' key competitors?
Some companies that are related to Castle Biosciences include Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS) and Cancer Genetics (CGIX).
What other stocks do shareholders of Castle Biosciences own?
Who are Castle Biosciences' key executives?
Castle Biosciences' management team includes the folowing people:
- Mr. Derek J. Maetzold, Founder, CEO, Pres & Director (Age 57)
- Mr. Frank Stokes, Chief Financial Officer (Age 49)
- Mr. Bernhard E. Spiess, Chief Operating Officer (Age 59)
- Mr. Toby W. Juvenal, Sr. VP of Sales (Age 59)
- Ms. Kristen Oelschlager R.N., RN, Sr. VP of Clinical Operations (Age 51)
When did Castle Biosciences IPO?
(CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
When did Castle Biosciences' quiet period expire?
Castle Biosciences' quiet period expired on Tuesday, September 3rd. Castle Biosciences had issued 4,000,000 shares in its public offering on July 25th. The total size of the offering was $64,000,000 based on an initial share price of $16.00. During Castle Biosciences' quiet period, underwriters and any insiders involved in the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Castle Biosciences?
Shares of CSTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Castle Biosciences' stock price today?
One share of CSTL stock can currently be purchased for approximately $21.95.
How big of a company is Castle Biosciences?
What is Castle Biosciences' official website?
How can I contact Castle Biosciences?
Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company can be reached via phone at 866-788-9007 or via email at [email protected]
MarketBeat Community Rating for Castle Biosciences (NASDAQ CSTL)
MarketBeat's community ratings are surveys of what our community members think about Castle Biosciences and other stocks. Vote "Outperform" if you believe CSTL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSTL will underperform the S&P 500 over the long term. You may vote once every thirty days.
